Ernexa Therapeutics CEO Sanjeev Luther shares how clinical research has revealed why certain cancers resist treatment and how emerging cell therapies may help break through those defenses.
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- Active Versus Passive Shipping Solutions For Clinical Shipments
- January 2026 — CDMO Opportunities And Threats Report
- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones
- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- Why Clinical Supply Risk Starts With Demand Signals
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Evolving Landscape Of Payer Coverage For CGTs: Trends And Insights
Examine how proactive payer engagement and robust clinical evidence regarding comparative effectiveness and durability of response can overcome significant reimbursement barriers and enhance patient access.
-
Optimizing Virus Bank Manufacturing
Gain insight into two cases where clients were enabled to overcome obstacles during virus bank manufacturing.
-
mRNA Purification Using Anion Exchange Chromatography At Ambient Temperature
Explore how anion exchange chromatography with dual gradient elution enables efficient mRNA purification at ambient temperature.
-
Fast And Accurate Detection Of Alzheimer's Disease Targets
In this study, the detection of three Alzheimer’s disease targets are highlighted: Human BDNF (Brain-derived neurotrophic factor), Tau, and TREM2 (Triggering receptor expressed on myeloid cells 2).
-
Ensuring cGMP Compliance In Cell And Gene Therapy Manufacturing
Discover how adhering to strict GMP guidelines and advanced equipment design ensures that complex, sterile cell and gene therapies are safely and effectively delivered.
-
Non Animal Origin Squalene For High-Risk Applications
Explore an ethical and sustainable alternative to shark-derived squalene that is backed by robust data to deliver identical performance in vaccine formulations without environmental compromise.
-
Intuitive Bioprocess Scale-Up From Bench Scale To Pilot Scale
This study explores scaling a high-demand fed-batch process from bench to pilot scale, highlighting control parameter differences at 50L and 500L while maintaining consistent growth and product titers.
-
A Digital Solution Embeds Quality Into Cellular Therapeutics Production
Discover how Dendreon cut review and release time by nearly 50% while maintaining a 99% right-first-time rate, which boosts collaboration, visibility, and operational efficiency across teams.
-
Screening Peptones, Including "Titration And Blending" Protocol Examples
Dive into the importance of peptone selection, instructions for reconstituting peptone powders for mammalian cell culture, and discover starter packs containing commonly used peptones for specific applications.
-
Understanding Immunogenicity In AAV Gene Therapy
As adeno-associated virus-based gene therapies progress toward clinical use, effectively managing immunogenicity risk is critical to patient selection, therapeutic durability, and regulatory success.
NEWSLETTER ARCHIVE
- 02.20.26 -- Deciding When Research Grade Raw Materials Are Sufficient
- 02.19.26 -- Advancing Your Cell and Gene Therapy Journey
- 02.19.26 -- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones
- 02.18.26 -- Specialized Fill/Finish For Advanced Therapies
- 02.18.26 -- Cold-Chain Packaging Strategies For Scaling Gene Therapies
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections